Objective: To establish reliability and validity of the Guy's Neurological Disability Scale (GNDS) for the assessment of patients with multiple sclerosis (MS) and to investigate whether it can be used by postal questionnaire.
Design: An observational study assessing one group of 22 patients using the GNDS face-to-face, repeating the assessment two or three weeks later with other tests; and assessing a second group of 21 patients first using a postal version of the GNDS and then seeing them face-to-face.
Setting: Patients in the community attending a day centre or a voluntary support group.
Subjects: Patients with multiple sclerosis.
Measures: The GNDS was the primary measure, and was compared with the Barthel Index, the Expanded Disability Status Scale (EDSS), the Short Orientation Concentration and Memory Test, the Nine-hole Peg Test, the Rivermead Mobility Index, the Hospital Anxiety and Depression Scale, the Fatigue Severity Scale, visual acuity assessment, swallowing 50 ml of water, and a clinical assessment of dysarthria.
Results: The test–retest reliability of the GNDS total score (r = 0.972) and each of its components (r varied from 0.685 to 0.987) was good. When compared with the EDSS or the Barthel, the GNDS had good validity (respectively r = 0.636 and r = –0.757). The validity was also measured for the different areas of the GNDS by comparison with corresponding indices or test. The results varied from good to excellent (r from –0.557 to 0.910). The results were only a little less reliable when a postal questionnaire was used.
Conclusion: The GNDS is a valid and reliable tool for the assessment of MS patients. The test–retest correlation varies from good to excellent. It can be used as postal questionnaire even if, as expected, the intervieweradministered method shows slightly better results.
Get full access to this article
View all access options for this article.
References
1.
Sharrack B, Hughes RAC, Soudain S. Guy's Neurological Disability Scale. Sixth meeting of the European Neurological Society. J Neurol1996; 243(suppl): 6–6.
2.
Sharrack B, Hughes RAC. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Multiple Sclerosis1999; 5: 223–233.
3.
Tubridy N, Behan PO, Capildeo R et al. and The UK Antegren Study Group. The effect of anti-a4 integrin antibody on brain lesion activity in MS. Neurology1999; 53: 466–472.
4.
Kurtzke JF. A new scale for evaluating the disability in multiple sclerosis. Neurology1955; 5: 580–583.
5.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983; 33: 1444–1452.
6.
World Health Organization. ICIDH-2: International Classification of Functioning and Disability. Beta-2 draft, Full version. Geneva: World Health Organization, 1999.
7.
Wade DT, de Jong B. Recent advances in rehabilitation. BMJ2000; 320: 1385–1358.
8.
Goodkin DE, Herstgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box and block and nine hole peg tests. Arch Phys Med Rehabil1988; 69: 850–854.
9.
Cutter GR, Baier ML, Rudick RA et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain1999; 122: 871–882.
10.
Noseworthy JH, Vandrvoort MK, Wong CJ, Ebers GC and the Canadian Cooperative MS Study Group. Interrater variability with the Expended Disability Statue Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurology1990; 40: 971–975.
11.
Sharrack B, Hughes RA. Reliability of distance estimation by doctors and patients: cross sectional study. BMJ1997; 315: 1652–1654.
12.
Fuller KJ, Dawson K, Wiles CM. Physiotherapy in chronic multiple sclerosis: a controlled trial. Clin Rehabil1996; 10: 195–204.
13.
Vaney C, Blaurock H, Gattlen B, Meisels C. Assessing mobility in multiple sclerosis using the Rivermead Mobility Index and gait speed. Clin Rehabil1996; 10: 216–226.
14.
Hauser SL, Dawson DM, Lehrich JR et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med1983; 308: 173–180.
15.
Mickey MR, Ellison GW, Myers LW. An illness severity score for multiple sclerosis. Neurology1984; 34: 1343–1347.
16.
Gulick EE. Model confirmation of the MS-Related Symptom Checklist. Nursing Res1989; 38: 147–153.
17.
Gulick EE. Parsimony and model confirmation of the ADL Self-Care Scale for multiple sclerosis persons. Nursing Res1987; 36: 278–283.
18.
De Souza LH. The development of a scale of the Guttman type for the assessment of mobility disability in multiple sclerosis. Clin Rehabil1999; 13: 476–481.
19.
Lankhorst GJ, Jelles F, Smits RCF et al. Quality of life in multiple sclerosis: the disability and impact profile (DIP). J Neurol1996; 243: 469–474.
20.
Cella DF, Dineen K, Arnason B et al. Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument. Neurology1996; 47: 129–139.
21.
Pfennings LEMA, Van der Ploeg HM, Cohen L et al. A health-related quality of life questionnaire for multiple sclerosis patients. Acta Neurol Scand1999; 100: 148–155.
22.
Solari A, Filippini G, Mendozzi L et al. Validation of Italian multiple sclerosis quality of life 54 questionnaire. J Neurol Neurosurg Psychiatry1999; 67: 158–162.
23.
Poser VM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guideline for research protocols. Ann Neurol1983; 13: 227–231.
24.
Wade DT, Collin C. The Barthel ADL Index: a standard measure of disability?Int Disabil Stud1988; 10: 64–67.
25.
Wade DT, Vergis E. The short orientation-memoryconcentration test: a study of its reliability and validity. Clin Rehabil1999; 13: 164–170.
26.
Mathiowetz V, Weber K, Kashman N, Volland G. Adult norms for the nine-hole peg test of finger dexterity. Occup Ther J Res1985; 5: 24–37.
27.
Collen FM, Wade DT, Robb GF, Bradshaw CM. The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment. Int Disabil Stud1991; 13: 50–54.
28.
Zigmond AS, Snaith RP. The Hospital Anxiety and Depression scale. Acta Psychiatr Scand1983; 67: 361–370.
29.
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AF. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol1989; 46: 1121–1123.
30.
DePippo, KL, Holas MA, Reding MJ. Validation of the 3-oz water swallow test for aspiration following stroke. Arch Neurol1992; 49: 1259–1261.
31.
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet1986; i: 307–310.
